Phase 2/3 Neurology Deal Benchmarks

Median Upfront

$536M

Range: $293M - $769M

Total Deal Value

$3.5B

Range: $2.3B - $4.8B

Royalty Rate

14.8% - 22.2%

Tiered up to 26.2%

Dev Milestones

$722M

Range: $483M - $964M

Model Your Deal

Market Analysis

Phase 2/3 neurology licensing deals carry a median total deal value of $3.5B, with upfront payments ranging from $293M to $769M. At this stage, deal structures are balanced between upfront and milestone payments, reflecting the proof-of-concept inflection. The recommended split allocates 15% to upfront and 85% to milestones.

The neurology landscape at the phase 2/3 stage is characterized by moderate competitive intensity with significant unmet need in neurodegenerative indications. Development milestones average $722M, regulatory milestones contribute $1.1B, and commercial milestones reach $1.2B. Disease-modifying therapies and novel CNS delivery platforms are attracting increasing licensee interest following breakthroughs in amyloid-targeted approaches.

Royalty rates for phase 2/3 neurology deals range from 14.8% to 22.2% at the base tier, with high-tier escalation to 26.2%. Mid-stage royalties reflect the balance of de-risking achieved and remaining development investment.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for phase 2/3 neurology deals?

Phase 2/3 neurology deals average $536M in upfront payments, ranging from $293M to $769M. The upfront allocation of 15% of total deal value reflects the clinical stage risk profile.

How are phase 2/3 neurology deal milestones structured?

Milestones account for approximately 85% of total deal value. Development milestones ($722M) represent the largest component, followed by commercial milestones ($1.2B) and regulatory milestones ($1.1B).

What royalty rates are typical for phase 2/3 neurology licensing?

Base royalty rates range from 14.8% to 22.2%, with tiered escalation to 18.8%-26.2% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Phase 2/3 Neurology Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Preclinical Neurology Deals

Phase 1 Neurology Deals

Phase 2/3 Oncology Deals

Phase 2/3 Immunology & Autoimmune Deals

Ready to Calculate Your Deal Terms?